Jon Paul Gockerman
Professor Emeritus of Medicine
My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.
The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.
Current Appointments & Affiliations
- Professor Emeritus of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013
Contact Information
- 25154 Morris Bldg, Durham, NC 27710
- Duke Box 3872, Durham, NC 27710
-
gocke002@mc.duke.edu
(919) 684-8964
- Background
-
Education, Training, & Certifications
- M.D., The University of Chicago 1967
-
Previous Appointments & Affiliations
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1983 - 2014
- Professor of Medicine, Medicine, Hematological Malignancies, Medicine 1994 - 2012
- Associate Professor of Medicine with tenure in the Department of Medicine, Medicine, Medical Oncology, Medicine 1984 - 1994
- Research
-
Selected Grants
- Cancer And Leukemia Group B awarded by National Institutes of Health 1993 - 1998
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.Full Text Link to Item
-
DiLillo, D. J., J. B. Weinberg, A. Yoshizaki, M. Horikawa, J. M. Bryant, Y. Iwata, T. Matsushita, et al. “Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.” Leukemia 27, no. 1 (January 2013): 170–82. https://doi.org/10.1038/leu.2012.165.Full Text Link to Item
-
Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.Full Text
-
Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.Full Text Link to Item
-
Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.Full Text Link to Item
-
Ettinger, David S., Mark Agulnik, Justin M. M. Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, Panagiotis M. Fidias, et al. “NCCN Clinical Practice Guidelines Occult primary.” J Natl Compr Canc Netw 9, no. 12 (December 2011): 1358–95. https://doi.org/10.6004/jnccn.2011.0117.Full Text Link to Item
-
Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.Full Text Link to Item
-
Lanasa, M. C., S. D. Allgood, S. L. Slager, S. S. Dave, C. Love, G. E. Marti, N. E. Kay, et al. “Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.” Leukemia 25, no. 9 (September 2011): 1459–66. https://doi.org/10.1038/leu.2011.117.Full Text Link to Item
-
Schuster, Stephen J., Sattva S. Neelapu, Barry L. Gause, John E. Janik, Franco M. Muggia, Jon P. Gockerman, Jane N. Winter, et al. “Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.” J Clin Oncol 29, no. 20 (July 10, 2011): 2787–94. https://doi.org/10.1200/JCO.2010.33.3005.Full Text Link to Item
-
Nalesnik, M. A., E. S. Woodle, J. M. Dimaio, B. Vasudev, L. W. Teperman, S. Covington, S. Taranto, et al. “Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.” Am J Transplant 11, no. 6 (June 2011): 1140–47. https://doi.org/10.1111/j.1600-6143.2011.03565.x.Full Text Link to Item
-
Zelenetz, Andrew D., Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, et al. “Non-Hodgkin's lymphomas.” J Natl Compr Canc Netw 9, no. 5 (May 2011): 484–560. https://doi.org/10.6004/jnccn.2011.0046.Full Text Link to Item
-
Bullock, Karen E., William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S Yousuf Zafar, et al. “A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).” Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465–74. https://doi.org/10.1007/s00280-010-1507-6.Full Text Link to Item
-
Mowery, Y. M., J. B. Weinberg, M. N. Kennedy, K. M. Bond, J. O. Moore, M. C. Lanasa, J. P. Gockerman, et al. “LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.” Leukemia 24, no. 9 (September 2010): 1580–87. https://doi.org/10.1038/leu.2010.150.Full Text Link to Item
-
Crout, Christopher A., Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos Decastro, Gwynn D. Long, Louis Diehl, et al. “Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.” Cancer Invest 28, no. 6 (July 2010): 654–60. https://doi.org/10.3109/07357901003631015.Full Text Link to Item
-
Zelenetz, Andrew D., Jeremy S. Abramson, Ranjana H. Advani, C Babis Andreadis, John C. Byrd, Myron S. Czuczman, Luis Fayad, et al. “NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.” J Natl Compr Canc Netw 8, no. 3 (March 2010): 288–334. https://doi.org/10.6004/jnccn.2010.0021.Full Text Link to Item
-
Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.” Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.Full Text Link to Item
-
Lanasa, M. C., S. D. Allgood, A. D. Volkheimer, J. P. Gockerman, J. F. Whitesides, B. K. Goodman, J. O. Moore, J. B. Weinberg, and M. C. Levesque. “Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.” Leukemia 24, no. 1 (January 2010): 133–40. https://doi.org/10.1038/leu.2009.192.Full Text Link to Item
-
Dugan, Elizabeth, Roxanne Truax, Kellen L. Meadows, Gerald C. Blobe, Michael A. Morse, Nishan H. Fernando, Jon P. Gockerman, William P. Petros, and Herbert I. Hurwitz. “Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.” Anticancer Res 29, no. 12 (December 2009): 5149–53.Link to Item
-
Friedman, Daphne R., J Brice Weinberg, William T. Barry, Barbara K. Goodman, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, et al. “A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.” Clin Cancer Res 15, no. 22 (November 15, 2009): 6947–55. https://doi.org/10.1158/1078-0432.CCR-09-1132.Full Text Link to Item
-
Byrd, John C., Bercedis L. Peterson, Kanti R. Rai, David Hurd, Raymond Hohl, Michael C. Perry, Jon Gockerman, Sreenivasa Nattam, and Richard A. Larson. “Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.” Leuk Lymphoma 50, no. 10 (October 2009): 1589–96. https://doi.org/10.1080/10428190903150839.Full Text Link to Item
-
Smith, S. M., J. Johnson, B. D. Cheson, G. Canellos, G. Petroni, M. Oken, D. Duggan, et al. “Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.” Leuk Lymphoma 50, no. 10 (October 2009): 1606–17. https://doi.org/10.1080/10428190903093807.Full Text Link to Item
-
Rizzieri, David A., Jenny A. O’Brien, Gloria Broadwater, Carlos M. Decastro, Prakash Dev, Louis Diehl, Anne Beaven, et al. “Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.” Cancer 115, no. 13 (July 1, 2009): 2922–29. https://doi.org/10.1002/cncr.24379.Full Text Link to Item
-
Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P134 A phase II pilot study of sorafenib in patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70215-2.Full Text
-
Castro, C. de, D. Adams, D. Rizzieri, J. Moore, J. Gockerman, L. Diehl, M. Horwitz, E. Edmonds, and J. Warzecho. “P129 A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes.” Leukemia Research 33, no. SUPPL. 1 (May 1, 2009). https://doi.org/10.1016/S0145-2126(09)70210-3.Full Text
-
Lanasa, Mark C., Sallie D. Allgood, Karen M. Bond, Jon P. Gockerman, Marc C. Levesque, and J Brice Weinberg. “Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL.” Br J Haematol 145, no. 4 (May 2009): 535–37. https://doi.org/10.1111/j.1365-2141.2009.07635.x.Full Text Link to Item
-
Shea, Thomas C., Anne W. Beaven, Dominic T. Moore, Jonathan S. Serody, Don A. Gabriel, Nelson Chao, Jon P. Gockerman, Reynaldo A. Garcia, and David A. Rizzieri. “Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.” Leuk Lymphoma 50, no. 5 (May 2009): 741–48. https://doi.org/10.1080/10428190902853136.Full Text Link to Item
-
Weinberg, J. B., A. D. Volkheimer, M. Mihovilovic, N. Jiang, Y. Chen, K. Bond, J. O. Moore, et al. “Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.” Leukemia 22, no. 12 (December 2008): 2184–92. https://doi.org/10.1038/leu.2008.241.Full Text Link to Item
-
Ettinger, David S., Mark Agulnik, Mihaela Cristea, Keith Eaton, Panagiotis M. Fidias, Jon P. Gockerman, Omar Hameed, et al. “Occult primary.” J Natl Compr Canc Netw 6, no. 10 (November 2008): 1026–60. https://doi.org/10.6004/jnccn.2008.0078.Full Text Link to Item
-
Armstrong, Andrew J., Patricia Creel, James Turnbull, Cassandra Moore, Tracy A. Jaffe, Sherri Haley, William Petros, et al. “A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.” Clin Cancer Res 14, no. 19 (October 1, 2008): 6270–76. https://doi.org/10.1158/1078-0432.CCR-08-1085.Full Text Link to Item
-
Rao, Arati V., Islam R. Younis, Gregory J. Sand, Ivan Spasojevic, David J. Adams, Carlos M. Decastro, John P. Gockerman, et al. “Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.” Leuk Lymphoma 49, no. 8 (August 2008): 1523–29. https://doi.org/10.1080/10428190802210700.Full Text Link to Item
-
Levesque, Marc C., Dipak K. Ghosh, Bethany E. Beasley, Youwei Chen, Alicia D. Volkheimer, Charles W. O’Loughlin, Jon P. Gockerman, Joseph O. Moore, and J Brice Weinberg. “CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant.” Leuk Res 32, no. 7 (July 2008): 1061–70. https://doi.org/10.1016/j.leukres.2007.11.026.Full Text Link to Item
-
Zafar, S Yousuf, David N. Howell, and Jon P. Gockerman. “Malignancy after solid organ transplantation: an overview.” Oncologist 13, no. 7 (July 2008): 769–78. https://doi.org/10.1634/theoncologist.2007-0251.Full Text Link to Item
-
Zelenetz, Andrew D., Ranjana H. Advani, John C. Byrd, Myron S. Czuczman, Lloyd E. Damon, Madeleine Duvic, Luis Fayad, et al. “Non-Hodgkin's lymphomas.” J Natl Compr Canc Netw 6, no. 4 (April 2008): 356–421. https://doi.org/10.6004/jnccn.2008.0030.Full Text Link to Item
-
Sevilla, Deborah W., Jerald Z. Gong, Barbara K. Goodman, Patrick J. Buckley, Philip Rosoff, Jon P. Gockerman, and Anand S. Lagoo. “Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.” Am J Clin Pathol 128, no. 6 (December 2007): 981–91. https://doi.org/10.1309/C1PP15P7CDB8UY39.Full Text Link to Item
-
Weinberg, J Brice, Alicia D. Volkheimer, Youwei Chen, Bethany E. Beasley, Ning Jiang, Mark C. Lanasa, Daphne Friedman, et al. “Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.” Am J Hematol 82, no. 12 (December 2007): 1063–70. https://doi.org/10.1002/ajh.20987.Full Text Link to Item
-
DeAngelo, Daniel J., Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, and Richard A. Larson. “Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.” Blood 109, no. 12 (June 15, 2007): 5136–42. https://doi.org/10.1182/blood-2006-11-056754.Full Text Link to Item
-
Arcasoy, Murat O., and Jon P. Gockerman. “Aplastic anaemia as an autoimmune complication of thymoma.” Br J Haematol 137, no. 4 (May 2007): 272. https://doi.org/10.1111/j.1365-2141.2007.06523.x.Full Text Link to Item
-
Peterson, Bruce A., Jeffrey Johnson, Margaret A. Shipp, Maurice Barcos, Jon P. Gockerman, George P. Canellos, and George P. Cancer and Leukemia Group B 9351. “High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.” Leuk Lymphoma 48, no. 5 (May 2007): 870–80. https://doi.org/10.1080/10428190701259758.Full Text Link to Item
-
Rizzieri, David A., Liang Piu Koh, Gwynn D. Long, Cristina Gasparetto, Keith M. Sullivan, Mitchell Horwitz, John Chute, et al. “Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.” J Clin Oncol 25, no. 6 (February 20, 2007): 690–97. https://doi.org/10.1200/JCO.2006.07.0953.Full Text Link to Item
-
Volkheimer, Alicia D., J Brice Weinberg, Bethany E. Beasley, John F. Whitesides, Jon P. Gockerman, Joseph O. Moore, Garnett Kelsoe, Barbara K. Goodman, and Marc C. Levesque. “Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification.” Blood 109, no. 4 (February 15, 2007): 1559–67. https://doi.org/10.1182/blood-2006-05-020644.Full Text Link to Item
-
Byrne, Brian J., and Jon P. Gockerman. “Salvage therapy in Hodgkin's lymphoma.” Oncologist 12, no. 2 (February 2007): 156–67. https://doi.org/10.1634/theoncologist.12-2-156.Full Text Link to Item
-
Zelenetz, Andrew D., Ranjana H. Advani, Francis Buadi, Fernando Cabanillas, Michael A. Caligiuri, Myron S. Czuczman, Lloyd E. Damon, et al. “Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.” J Natl Compr Canc Netw 4, no. 3 (March 2006): 258–310. https://doi.org/10.6004/jnccn.2006.0025.Full Text Link to Item
-
Koontz, Bridget F., John P. Kirkpatrick, Robert W. Clough, Robert G. Prosnitz, Jon P. Gockerman, Joseph O. Moore, and Leonard R. Prosnitz. “Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.” J Clin Oncol 24, no. 4 (February 1, 2006): 605–11. https://doi.org/10.1200/JCO.2005.02.9850.Full Text Link to Item
-
Levesque, Marc C., Youwei Chen, Bethany E. Beasley, Charles W. O’Loughlin, Jon P. Gockerman, Joseph O. Moore, and J Brice Weinberg. “Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels.” Leuk Res 30, no. 1 (January 2006): 24–28. https://doi.org/10.1016/j.leukres.2005.05.022.Full Text Link to Item
-
Simsir, Sinan A., Shu S. Lin, Laura J. Blue, John P. Gockerman, Stuart D. Russell, and Carmelo A. Milano. “Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.” Ann Thorac Surg 80, no. 2 (August 2005): 717–19. https://doi.org/10.1016/j.athoracsur.2004.02.036.Full Text Link to Item
-
Neelapu, Sattva S., Barry L. Gause, Daniel A. Nikcevich, Stephen J. Schuster, Jane Winter, Jon P. Gockerman, Thomas Loughran, et al. “Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.” Clin Lymphoma 6, no. 1 (June 2005): 61–64. https://doi.org/10.3816/clm.2005.n.031.Full Text Link to Item
-
Ettinger, David S., Juan P. Arnoletti, Jon P. Gockerman, Charles Handorf, Kathleen Anne Havlin, Charlotte D. Jacobs, Milind Javle, et al. “Occult primary cancer clinical practice guidelines.” J Natl Compr Canc Netw 3, no. 2 (March 2005): 214–33.Link to Item
-
Safford, Shawn D., R Edward Coleman, Jon P. Gockerman, Joseph Moore, Jerome Feldman, Mark W. Onaitis, Douglas S. Tyler, and John A. Olson. “Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients.” Cancer 101, no. 9 (November 1, 2004): 1987–93. https://doi.org/10.1002/cncr.20592.Full Text Link to Item
-
Talbot, Jeffrey, Valerie K. Ibom, David A. Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M. DeCastro, Joseph O. Moore, et al. “Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.” Clin Lymphoma 5, no. 2 (September 2004): 116–22. https://doi.org/10.3816/clm.2004.n.018.Full Text Link to Item
-
Rizzieri, David A., Gamal Akabani, Michael R. Zalutsky, R Edward Coleman, Scott D. Metzler, James E. Bowsher, Bonnie Toaso, et al. “Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.” Blood 104, no. 3 (August 1, 2004): 642–48. https://doi.org/10.1182/blood-2003-12-4264.Full Text Link to Item
-
Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.” Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.Full Text Link to Item
-
Gluck, William Larry, Deborah Hurst, Alan Yuen, Alexandra M. Levine, Mark A. Dayton, Jon P. Gockerman, Jennifer Lucas, et al. “Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.” Clin Cancer Res 10, no. 7 (April 1, 2004): 2253–64. https://doi.org/10.1158/1078-0432.ccr-1087-3.Full Text Link to Item
-
Ibom, Valerie K., Robert G. Prosnitz, Jerald Z. Gong, Joseph O. Moore, Carlos M. DeCastro, Leonard R. Prosnitz, David A. Rizzieri, and Jon P. Gockerman. “Rituximab in lymphocyte predominance Hodgkin's disease: a case series.” Clin Lymphoma 4, no. 2 (September 2003): 115–18. https://doi.org/10.3816/clm.2003.n.021.Full Text Link to Item
-
Talbot, Jeffrey, David A. Rizzieri, Carlos M. DeCastro, Joseph O. Moore, Patrick Buckley, Rhonda Laney, Diane Stevenson, Heather Brumbaugh, and Jon P. Gockerman. “High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.” Am J Hematol 73, no. 4 (August 2003): 295–96. https://doi.org/10.1002/ajh.10362.Full Text Link to Item
-
Advani, Anjali S., Benjamin Atkeson, Carrie L. Brown, Bercedis L. Peterson, Laura Fish, Jeffrey L. Johnson, Jon P. Gockerman, and Marc Gautier. “Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.” Cancer 97, no. 6 (March 15, 2003): 1499–1506. https://doi.org/10.1002/cncr.11213.Full Text Link to Item
-
Rizzieri, David A., Valerie K. Ibom, Joseph O. Moore, Carlos M. DeCastro, Gary L. Rosner, David J. Adams, Traci Foster, et al. “Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.” Clin Cancer Res 9, no. 2 (February 2003): 663–68.Link to Item
-
Bass, Adam J., Jon P. Gockerman, Eve Hammett, Carlos M. DeCastro, David J. Adams, Gary L. Rosner, Nancy Payne, et al. “Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.” J Clin Oncol 20, no. 13 (July 1, 2002): 2995–3000. https://doi.org/10.1200/JCO.2002.08.166.Full Text Link to Item
-
Shah, Manish A., Linda Sanders, Kevin Lanclos, Anna Lisa Chamis, Jon Gockerman, Dannah Wray, G Ralph Corey, and Vance G. Fowler. “Staphylococcus aureus bacteremia in patients with neutropenia.” South Med J 95, no. 7 (July 2002): 782–84. https://doi.org/10.1097/00007611-200207000-00029.Full Text Link to Item
-
McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.” Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.Full Text Link to Item
-
Rizzieri, David A., Adam J. Bass, Gary L. Rosner, Jon P. Gockerman, Carlos M. DeCastro, William P. Petros, David J. Adams, et al. “Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.” J Clin Oncol 20, no. 3 (February 1, 2002): 674–79. https://doi.org/10.1200/JCO.2002.20.3.674.Full Text Link to Item
-
McCune, S. L., J. P. Gockerman, and D. A. Rizzieri. “Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma.” Jama 286, no. 10 (September 12, 2001): 1149–52. https://doi.org/10.1001/jama.286.10.1149.Full Text Link to Item
-
Bartlett, N. L., G. R. Petroni, B. A. Parker, N. D. Wagner, J. P. Gockerman, G. A. Omura, G. P. Canellos, M. Robert, J. L. Johnson, and B. A. Peterson. “Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.” Cancer 92, no. 2 (July 15, 2001): 207–17. https://doi.org/10.1002/1097-0142(20010715)92:2<207::aid-cncr1311>3.0.co;2-d.Full Text Link to Item
-
Rizzieri, D. A., J. P. Gockerman, C. M. Decastro, S. Lilly, and T. Foster. “Phase i trial of continuously infused gemcitabine with cpt-11 for refractory hematologic malignancies.” Blood 96, no. 11 PART II (December 1, 2000).
-
Agarwal, S., J. P. Gockerman, M. D. Aldous, and M. W. Swaim. “Primary central nervous system lymphoma, presenting as diabetes insipidus, as a sequela of hepatitis C.” Am J Med 107, no. 3 (September 1999): 303–4. https://doi.org/10.1016/s0002-9343(99)00181-3.Full Text Link to Item
-
Liu, K., K. P. Mann, K. M. Vitellas, E. K. Paulson, R. C. Nelson, J. P. Gockerman, and L. G. Dodd. “Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas.” Diagn Cytopathol 21, no. 2 (August 1999): 98–104. https://doi.org/10.1002/(sici)1097-0339(199908)21:2<98::aid-dc4>3.0.co;2-v.Full Text Link to Item
-
Iselin, C. E., R. A. Leder, J. Lacey, J. P. Gockerman, and D. F. Paulson. “Renal lymphoma in an azotemic patient--usefulness of magnetic resonance imaging.” Scand J Urol Nephrol 33, no. 2 (April 1999): 129–30. https://doi.org/10.1080/003655999750016131.Full Text Link to Item
-
Lau, C. L., R. C. Bentley, J. P. Gockerman, L. G. Que, and T. A. D’Amico. “Malignant melanoma presenting as a mediastinal mass.” Ann Thorac Surg 67, no. 3 (March 1999): 851–52. https://doi.org/10.1016/s0003-4975(99)00075-2.Full Text Link to Item
-
Perry, J. R., M. T. Brown, and J. P. Gockerman. “Acute leukemia following treatment of malignant glioma.” J Neurooncol 40, no. 1 (October 1998): 39–46. https://doi.org/10.1023/a:1006175831785.Full Text Link to Item
-
Hanson, M. W., A. M. Schneider, D. S. Enterline, J. M. Feldman, and J. P. Gockerman. “Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit.” J Nucl Med 39, no. 4 (April 1998): 647–50.Link to Item
-
Laughlin, M. J., D. S. McGaughey, J. R. Crews, N. J. Chao, D. Rizzieri, M. Ross, J. Gockerman, et al. “Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.” J Clin Oncol 16, no. 3 (March 1998): 1008–12. https://doi.org/10.1200/JCO.1998.16.3.1008.Full Text Link to Item
-
Williams, E. “Thrombocytosis associated with low-molecular-weight heparin.” Ann Intern Med 126, no. 9 (May 1, 1997): 742–43. https://doi.org/10.7326/0003-4819-126-9-199705010-00024.Full Text Link to Item
-
Rizzieri, D. A., W. M. Wong, and J. P. Gockerman. “Thrombocytosis associated with low-molecular-weight heparin.” Ann Intern Med 125, no. 2 (July 15, 1996): 157. https://doi.org/10.7326/0003-4819-125-2-199607150-00031.Full Text Link to Item
-
Shami, P. J., J. O. Moore, J. P. Gockerman, J. W. Hathorn, M. A. Misukonis, and J. B. Weinberg. “Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells.” Leuk Res 19, no. 8 (August 1995): 527–33. https://doi.org/10.1016/0145-2126(95)00013-e.Full Text Link to Item
-
Brown, M. T., R. E. McClendon, and J. P. Gockerman. “Primary central nervous system lymphoma with systemic metastasis: case report and review.” J Neurooncol 23, no. 3 (1995): 207–21. https://doi.org/10.1007/BF01059952.Full Text Link to Item
-
Lachance, D. H., D. M. Brizel, J. P. Gockerman, E. C. Halperin, P. C. Burger, O. B. Boyko, M. T. Brown, and S. C. Schold. “Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.” Neurology 44, no. 9 (September 1994): 1721–27. https://doi.org/10.1212/wnl.44.9.1721.Full Text Link to Item
-
Brizel, D. M., J. P. Gockerman, J. Crawford, J. W. Hathorn, J. O. Moore, B. Osborne, and L. R. Prosnitz. “A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease.” Cancer 74, no. 1 (July 1, 1994): 159–63. https://doi.org/10.1002/1097-0142(19940701)74:1<159::aid-cncr2820740125>3.0.co;2-x.Full Text Link to Item
-
Glantz, M. J., H. Biran, M. E. Myers, J. P. Gockerman, and M. H. Friedberg. “The radiographic diagnosis and treatment of paraneoplastic central nervous system disease.” Cancer 73, no. 1 (January 1, 1994): 168–75. https://doi.org/10.1002/1097-0142(19940101)73:1<168::aid-cncr2820730129>3.0.co;2-z.Full Text Link to Item
-
Gockerman, J. P., E. C. Halperin, G. C. Magrinat, B. M. Hendrix, and W. P. Peters. “Physician-assisted suicide and advance directives concerning life support.” N C Med J 54, no. 7 (July 1993): 312–16.Link to Item
-
Ortel, T. L., J. P. Gockerman, R. M. Califf, R. L. McCann, C. M. O’Connor, D. M. Metzler, and C. S. Greenberg. “Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis.” Thromb Haemost 67, no. 3 (March 2, 1992): 292–96.Link to Item
-
Persons, D. A., M. Laughlin, D. Tanner, J. Perfect, J. P. Gockerman, and J. W. Hathorn. “Fluconazole and Candida krusei fungemia.” N Engl J Med 325, no. 18 (October 31, 1991): 1315.Link to Item
-
Higa, G. M., J. P. Gockerman, A. L. Hunt, M. R. Jones, and B. J. Horne. “The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.” Cancer 68, no. 8 (October 15, 1991): 1691–93. https://doi.org/10.1002/1097-0142(19911015)68:8<1691::aid-cncr2820680805>3.0.co;2-w.Full Text Link to Item
-
Brizel, D. M., E. P. Winer, L. R. Prosnitz, J. Scott, J. Crawford, J. O. Moore, and J. P. Gockerman. “Improved survival in advanced Hodgkin's disease with the use of combined modality therapy.” Int J Radiat Oncol Biol Phys 19, no. 3 (September 1990): 535–42. https://doi.org/10.1016/0360-3016(90)90478-3.Full Text Link to Item
-
Jones, R. B., E. J. Shpall, J. Shogan, M. L. Affronti, D. Coniglio, L. Hart, E. Halperin, J. D. Iglehart, J. Moore, and J. Gockerman. “The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.” Cancer 66, no. 3 (August 1, 1990): 431–36. https://doi.org/10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x.Full Text Link to Item
-
Laszlo, J., D. Goldstein, J. Gockerman, L. Hood, A. T. Huang, P. Triozzi, W. D. Sedwick, H. Koren, E. H. Ellinwood, and C. Y. Tso. “Phase I studies of recombinant interferon-gamma.” J Biol Response Mod 9, no. 2 (April 1990): 185–93.Link to Item
-
Kaufman, P. A., J. P. Gockerman, and C. S. Greenberg. “Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature.” Am J Med 86, no. 5 (May 1989): 612–16. https://doi.org/10.1016/0002-9343(89)90396-3.Full Text Link to Item
-
Borowitz, M. J., J. P. Gockerman, J. O. Moore, C. I. Civin, S. O. Page, J. Robertson, and S. H. Bigner. “Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia.” Am J Clin Pathol 91, no. 3 (March 1989): 265–70. https://doi.org/10.1093/ajcp/91.3.265.Full Text Link to Item
-
Peters, W. P., A. Stuart, M. Klotman, C. Gilbert, R. B. Jones, E. J. Shpall, J. Gockerman, R. C. Bast, and J. O. Moore. “High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.” Cancer Chemother Pharmacol 23, no. 6 (1989): 377–83. https://doi.org/10.1007/BF00435840.Full Text Link to Item
-
Peters, W. P., E. J. Shpall, R. B. Jones, G. A. Olsen, R. C. Bast, J. P. Gockerman, and J. O. Moore. “High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.” J Clin Oncol 6, no. 9 (September 1988): 1368–76. https://doi.org/10.1200/JCO.1988.6.9.1368.Full Text Link to Item
-
Olsen, G. A., J. P. Gockerman, R. C. Bast, M. Borowitz, and W. P. Peters. “Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support.” Transplantation 46, no. 1 (July 1988): 57–60. https://doi.org/10.1097/00007890-198807000-00009.Full Text Link to Item
-
Sokal, J. E., J. P. Gockerman, and S. H. Bigner. “Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia.” Leuk Res 12, no. 6 (1988): 453–58. https://doi.org/10.1016/0145-2126(88)90110-5.Full Text Link to Item
-
Goldstein, D., J. Gockerman, R. Krishnan, J. Ritchie, C. Y. Tso, L. E. Hood, E. Ellinwood, and J. Laszlo. “Effects of gamma-interferon on the endocrine system: results from a phase I study.” Cancer Res 47, no. 23 (December 1, 1987): 6397–6401.Link to Item
-
Peters, W. P., W. D. Henner, L. B. Grochow, G. Olsen, S. Edwards, H. Stanbuck, A. Stuart, J. Gockerman, J. Moore, and R. C. Bast. “Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.” Cancer Res 47, no. 23 (December 1, 1987): 6402–6.Link to Item
-
Kurlander, R., R. E. Coleman, J. Moore, J. Gockerman, W. Rosse, and R. Siegal. “Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults.” Am J Med 83, no. 4A (October 23, 1987): 17–24. https://doi.org/10.1016/0002-9343(87)90546-8.Full Text Link to Item
-
Barton, J. C., E. F. Prasthofer, J. P. Gockerman, and C. E. Grossi. “Immune deficiency and expanded population of granular lymphocytes after bone marrow transplantation.” Am J Med 82, no. 5 (May 1987): 1086–87. https://doi.org/10.1016/0002-9343(87)90183-5.Full Text Link to Item
-
Gockerman, J. P., H. Silberman, and A. A. Bartolucci. “Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.” Cancer Treat Rep 71, no. 7–8 (1987): 773–74.Link to Item
-
Gockerman, J. P., E. N. Spremulli, M. Raney, and T. Logan. “Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.” Cancer Treat Rep 70, no. 10 (October 1986): 1199–1203.Link to Item
-
Gockerman, J. P., A. A. Bartolucci, M. O. Nelson, H. Silberman, E. Velez-Garcia, and R. Stein. “Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.” Cancer Treat Rep 70, no. 6 (June 1986): 801–2.Link to Item
-
Kramer, B. S., R. Birch, J. P. Gockerman, A. Greco, and K. Prestridge. “Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.” Cancer Treat Rep 70, no. 6 (June 1986): 803–4.Link to Item
-
Triozzi, P. L., M. J. Borowitz, and J. P. Gockerman. “Gastrointestinal involvement and multiple lymphomatous polyposis in mantle-zone lymphoma.” J Clin Oncol 4, no. 6 (June 1986): 866–73. https://doi.org/10.1200/JCO.1986.4.6.866.Full Text Link to Item
-
Gockerman, J. P., M. Raney, and T. Logan. “Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.” Cancer Treat Rep 69, no. 9 (September 1985): 1029–30.Link to Item
-
Wise, R. H., M. S. Shin, J. P. Gockerman, S. L. Zornes, E. Rubin, and P. H. Nath. “Pneumonia in bone marrow transplant patients.” Ajr Am J Roentgenol 143, no. 4 (October 1984): 707–14. https://doi.org/10.2214/ajr.143.4.707.Full Text Link to Item
-
Rodu, B., I. L. Griffin, and J. P. Gockerman. “Oral candidiasis in cancer patients.” South Med J 77, no. 3 (March 1984): 312–14. https://doi.org/10.1097/00007611-198403000-00011.Full Text Link to Item
-
Johnson, F. L., A. T. Look, J. Gockerman, M. R. Ruggiero, L. Dalla-Pozza, and F. T. B. III. “Bone-marrow transplantation in a patient with sickle-cell anemia.” New England Journal of Medicine 311, no. 12 (1984): 780–83.
-
Rodu, B., and J. P. Gockerman. “Oral manifestations of the chronic graft-v-host reaction.” Jama 249, no. 4 (January 28, 1983): 504–7.Link to Item
-
Gockerman, J. P. “Drug-induced interstitial lung diseases.” Clin Chest Med 3, no. 3 (September 1982): 521–36.Link to Item
-
Kirchner, K. A., R. M. Smith, J. P. Gockerman, and R. G. Luke. “Hereditary thrombotic thrombocytopenic purpura: microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurring in consecutive generations.” Nephron 30, no. 1 (1982): 28–30. https://doi.org/10.1159/000182427.Full Text Link to Item
-
Marciniak, E., and J. P. Gockerman. “Kinetics of elimination of antithrombin III concentrate in heparinized patients.” Br J Haematol 48, no. 4 (August 1981): 617–25. https://doi.org/10.1111/j.1365-2141.1981.00617.x.Full Text Link to Item
-
Gockerman, J. P. “Allogeneic bone marrow transplantation for aplastic anemia and acute leukemia.” Ala J Med Sci 18, no. 3 (July 1981): 235–39.Link to Item
-
Goldenberg, D. M., E. E. Kim, F. Deland, E. Spremulli, M. O. Nelson, J. P. Gockerman, F. J. Primus, R. L. Corgan, and E. Alpert. “Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein.” Cancer 45, no. 10 (May 15, 1980): 2500–2505. https://doi.org/10.1002/1097-0142(19800515)45:10<2500::aid-cncr2820451006>3.0.co;2-j.Full Text Link to Item
-
Gockerman, J. P., and W. Jacob. “Purification and characterization of papain-solubilized HLA antigens from human platelets.” Blood 53, no. 5 (May 1979): 838–50.Link to Item
-
Gockerman, J. P. “The lipids of the erythrocyte in paroxysmal nocturnal hemoglobinuria.” Am J Hematol 5, no. 4 (1978): 323–33. https://doi.org/10.1002/ajh.2830050407.Full Text Link to Item
-
Marciniak, E., and J. P. Gockerman. “Heparin-induced decrease in circulating antithrombin-III.” Lancet 2, no. 8038 (September 17, 1977): 581–84. https://doi.org/10.1016/s0140-6736(77)91429-5.Full Text Link to Item
-
Gockerman, J. P., and R. P. Brouillard. “RBC transfusions in paroxysmal nocturnal hemoglobinuria.” Arch Intern Med 137, no. 4 (April 1977): 536–38.Link to Item
-
Marciniak, E., and J. P. Gockerman. “Effect of heparin on circulating antithrombin III level.” Thrombosis and Haemostasis 38, no. 1 (January 1, 1977): 77. https://doi.org/10.1055/s-0039-1680522.Full Text
-
Marciniak, E., and J. P. Gockerman. “Effect of heparin therapy on antithrombin III.” Clinical Research 25, no. 3 (January 1, 1977).
-
Kimball, D. B., F. R. Rickles, J. P. Gockerman, B. G. Hattler, J. A. Light, and M. E. Conrad. “Procoagulant and platelet aggregating properties of antilymphocyte sera.” J Lab Clin Med 87, no. 5 (May 1976): 868–81.Link to Item
-
Gockerman, J. P., J. R. Durocher, and M. E. Conrad. “The abnormal surface characteristics of the red blood cell membrane in congenital dyserythropoietic anaemia type II (HEMPAS).” Br J Haematol 30, no. 4 (August 1975): 383–94. https://doi.org/10.1111/j.1365-2141.1975.tb01852.x.Full Text Link to Item
-
Joseph, K. C., and J. P. Gockerman. “Accumulation of glycolipids containing N-acetylglucosamine in erythrocyte stroma of patients with congenital dyserythropoietic anemia type II (HEMPAS).” Biochem Biophys Res Commun 65, no. 1 (July 8, 1975): 146–52. https://doi.org/10.1016/s0006-291x(75)80072-6.Full Text Link to Item
-
Alving, C. R., D. H. Conrad, J. P. Gockerman, M. B. Gibbs, and G. H. Wirtz. “Vitamin A in liposomes. Inhibition of complement binding and alteration of membrane structure.” Biochim Biophys Acta 394, no. 2 (June 25, 1975): 157–65. https://doi.org/10.1016/0005-2736(75)90253-9.Full Text Link to Item
-
Durocher, J. R., J. P. Gockerman, and M. E. Conrad. “Alteration of human erythrocyte membrane properties by complement fixation.” J Clin Invest 55, no. 4 (April 1975): 675–80. https://doi.org/10.1172/JCI107976.Full Text Link to Item
-
Gockerman, J. P., R. P. Bowman, and M. E. Conrad. “Detection of platelet isoantibodies by (3H)serotonin platelet release and its clinical application to the problem of platelet matching.” J Clin Invest 55, no. 1 (January 1975): 75–83. https://doi.org/10.1172/JCI107920.Full Text Link to Item
-
Joseph, K. C., J. P. Gockerman, and C. R. Alving. “Abnormal lipid composition of the red cell membrane in congenital dyserythropoietic anemia type II (HEMPAS).” J Lab Clin Med 85, no. 1 (January 1975): 34–40.Link to Item
-
Joseph, K. C., and J. P. Gockerman. “Accumulations of N acetyl glucosamine containing glycolipids in erythrocyte stroma of patients with congenial dyserythropoietic anemia type II (HEMPAS).” Clinical Research 23, no. 3 (January 1, 1975).
-
Gockerman, J. P., and N. R. Shulman. “Isoantibody specificity in post-transfusion purpura.” Blood 41, no. 6 (June 1973): 817–22.Link to Item
-
Logue, G. L., W. F. Rosse, and J. P. Gockerman. “Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome.” J Clin Invest 52, no. 2 (February 1973): 493–501. https://doi.org/10.1172/JCI107206.Full Text Link to Item
-
Enquist, R. W., J. P. Gockerman, E. H. Jenis, R. L. Warkel, and D. E. Dillon. “Type II congenital dyserythropoietic anemia.” Ann Intern Med 77, no. 3 (September 1972): 371–76. https://doi.org/10.7326/0003-4819-77-3-371.Full Text Link to Item
-
ALLEN, J. M., and J. GOCKERMAN. “ELECTROPHORETIC SEPARATION OF MULTIPLE FORMS OF PARTICLE ASSOCIATED.” Annals of the New York Academy of Sciences 121 (1964): 616–33.
-
-
Conference Papers
-
Gallagher, Scott F., Daphne W. Denham, Michel M. Murr, and James G. Norman. “The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism.” In Surgery, 134:910–17, 2003. https://doi.org/10.1016/s0039-6060(03)00414-8.Full Text Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.